Table 1.
CYP2C19 and CYP2C9 genotypes, phenotypes, and actionable medications
| Metabolizer phenotype | CYP2C19 genotype | Total | % of cohort | Patients with medication impact | Medications |
|---|---|---|---|---|---|
| Ultrarapid metabolizer | *17/*17 | 3 | 3% | 2 | Omeprazole, esomeprazole |
| Rapid metabolizer | *1/*17 | 24 | 26% | 8 | Clobazam, diazepam, lacosamide, omeprazole, sertraline, |
| Normal metabolizer | *1/*1 | 39 | 41% | NA | NA |
| Intermediate metabolizer | *1/*2 | 19 | 20% | 6 | Citalopram, clobazam, diazepam, esomeprazole, omeprazole, sertraline |
| *2/*17 | 4 | 4% | 1 | Omeprazole | |
| Poor metabolizer | *2/*2 | 5 | 5% | 2 | Diazepam, sertraline |
| Metabolizer phenotype | CYP2C9 genotype | Total | % of cohort | Patients with medication impact | Medications |
|---|---|---|---|---|---|
| Normal metabolizer | *1/*1 | 69 | 73% | NA | NA |
| Intermediate metabolizer | *1/*2 | 13 | 14% | 1 | No patients were taking medications with actionable or informative PGx recommendations for CYP2C9 variants |
| *1/*3 | 4 | 4% | 0 | ||
| Poor metabolizer | *2/*2 | 2 | 2% | 0 | |
| *2/*3 | 5 | 5% | 0 | ||
| *2/*6 | 1 | 1% | 0 |
CYP2C19: NG_008384.2; NC_000010.10; NM_000769.2; Build GRCh37.p13. CYP2C9: NG_008385.1; NC_000010.10; NM_000771.3; Build GRCh37.p13. NA = not applicable.